Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label combination therapy with GAD-alum, etanercept and vitamin D in newly diagnosed type 1 diabetes
2014-001323-76Phase 2Completed
- Sponsor
- Linköping University
- Start
- Jun 2014
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Diamyd, etanercept and cholecalciferol in diabetes mellitus type 1 (T1D), sponsored by Linköping University. Started Jun 2014; status: completed.
02
Drugs
Diamydetanerceptcholecalciferol
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2014-001323-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001323-76.